An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women with Invasive Breast Cancer or DCIS undergoing Mastectomy
A study for women with invasive breast cancer or DCIS undergoing mastectomy using study drug Faslodex
Sponsor: Atossa Genetics
Enrolling: Female Patients Only
IRB Number: AAAQ4357
U.S. Govt. ID: NCT02540330
Contact: Lyn Goldsmith: 212-342-0261 / lg2240@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to determine the safety and tolerability of Faslodex given directly into thebreast ducts of women with invasive breast cancer or Ductal Carcinoma In Situ (DCIS). This study is for women who have been diagnosed with invasive breast cancer or DCIS. DCIS is the presence of abnormal cells inside a milk duct in the breast, and your cancer or DCIS treatment includes removing the afflicted breast, also known as a mastectomy.
This study is closed
Investigator
Sheldon Feldman
Do You Qualify?
Are you scheduled to undergo a mastectomy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Lyn Goldsmith
lg2240@cumc.columbia.edu
212-342-0261